Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model

被引:71
作者
Liu, ZP [1 ]
Song, Y [1 ]
Zhang, XP [1 ]
Liu, ZQ [1 ]
Zhang, WZ [1 ]
Mao, WF [1 ]
Wang, W [1 ]
Cui, WM [1 ]
Zhang, X [1 ]
Jia, XD [1 ]
Li, N [1 ]
Han, C [1 ]
Liu, C [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Inst Nutr & Food Safety, Beijing 10050, Peoples R China
来源
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | 2005年 / 32卷 / 12期
关键词
angiotensin II; cardiac hypertrophy; nephrectomy; nitric oxide endothelin; rats; trans-resveratrol;
D O I
10.1111/j.1440-1681.2005.04303.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. trans-Resveratrol (resveratrol) has been shown to have beneficial effects on the cardiovascular system in a number of studies. It is, however, unclear whether this naturally occurring compound can protect against cardiac hypertrophy. The aim of the present study was to investigate the effects of resveratrol on cardiac hypertrophy in vivo and the potential underlying mechanisms involving endothelin (ET), angiotensin (Ang) II and nitric oxide (NO) in partially nephrectomized rats. 2. Animal models bearing cardiac hypertrophy were replicated in male Sprague-Dawley rats following partial nephrectomy (PNX). Resveratrol (10 or 50 mg/kg) was administered to rats by gavage for 4 weeks. Simultaneous PNX and sham operation controls were simultaneously established in the present study. The systolic blood pressure (SBP) of rats was measured at baseline and, along with heart weight, after 4 weeks treatment. Serum ET-1, AngII and NO concentrations were determined. 3. In the present study, it was shown that, compared with rats in the sham-operated group, rats in the PNX group had significantly higher SBP (154.1 +/- 22.7 mmHg), heart weight (1.69 +/- 0.24 g) and serum ET-1 (125.70 +/- 26.27 pg/mL) and AngII serum concentrations (743.63 +/- 86.50 pg/mL), whereas serum NO concentrations were lower (21.1 +/- 6.9 mu mol/L; all P < 0.05). These values in the sham control group were 114 +/- 10 mmHg, 1.28 +/- 0.13 g, 52.44 +/- 21.85 pg/mL, 528.7 +/- 158.5 pg/mL and 53.21 +/- 23.87 mu mol/L, respectively. After 4 weeks treatment with 50 mg/kg resveratrol, SBP, heart,weight and ET-1 and AngII concentrations had decreased to 135.4 +/- 15.8 mmHg, 1.39 +/- 0.15 g, 97.11 +/- 26.74 pg/mL and 629.64 +/- 116.18 pg/mL, respectively. However, the serum NO concentration had increased to 40.1 +/- 14.6 mu mol/L. These values were significantly different from those obtained for the PNX group. 4. In conclusion, trans-resveratrol appears to be able to protect against the increase in SBP and subsequent cardiac hypertrophy in vivo and the mechanisms responsible may involve, at least in part, modulation of NO, AngII and ET-1 production.
引用
收藏
页码:1049 / 1054
页数:6
相关论文
共 42 条
  • [1] Red wine polyphenols alone or in association with ethanol prevent hypertension, cardiac hypertrophy, and production of reactive oxygen species in the insulin-resistant fructose-fed rat
    Al-Awwadi, NA
    Bornet, A
    Azay, J
    Araiz, C
    Delbosc, S
    Cristol, JP
    Linck, N
    Cros, G
    Teissedre, PL
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2004, 52 (18) : 5593 - 5597
  • [2] [Anonymous], JINGJIXUE DONGTAI
  • [3] CHRONIC BLOCKADE OF NITRIC-OXIDE SYNTHESIS IN THE RAT PRODUCES SYSTEMIC HYPERTENSION AND GLOMERULAR DAMAGE
    BAYLIS, C
    MITRUKA, B
    DENG, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (01) : 278 - 281
  • [4] Blood pressure control early in diabetes: A balance between angiotensin II and nitric oxide
    Brands, MW
    Fitzgerald, SM
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2002, 29 (1-2) : 127 - 131
  • [5] Plant foods and herbal sources of resveratrol
    Burns, J
    Yokota, T
    Ashihara, H
    Lean, MEJ
    Crozier, A
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (11) : 3337 - 3340
  • [6] Myosin heavy chain expression and atrophy in rat skeletal muscle during transition from cardiac hypertrophy to heart failure
    Carvalho, RF
    Cicogna, AC
    Campos, GER
    De Assis, JMF
    Padovani, CR
    Okoshi, MP
    Pai-Silva, MD
    [J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2003, 84 (04) : 201 - 206
  • [7] Chen CK, 1996, GEN PHARMACOL-VASC S, V27, P363
  • [8] Chen Li-Na, 2003, Sheng Li Ke Xue Jin Zhan, V34, P272
  • [9] Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy
    Cheng, TH
    Liu, JC
    Lin, H
    Shih, NL
    Chen, YL
    Huang, MT
    Chan, P
    Cheng, CF
    Chen, JJ
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 (02) : 239 - 244
  • [10] Molecular and cellular mechanisms of myocardial failure
    Colucci, WS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (11A) : L15 - L25